MS Views and News Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter


MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click: www.youtube.com/msviewsandnews

Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Friday, May 30, 2014

Genzyme’s Lemtrada Resubmission Accepted for Review by FDA

CAMBRIDGE, Mass., May 30, 2014 (BUSINESS WIRE) -- Genzyme, a Sanofi company , announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. A six-month review period has been assigned for the Lemtrada sBLA. Genzyme expects FDA action on the sBLA in the fourth quarter.
This resubmission is based on data from the same clinical studies included in the original sBLA, and provides supplemental analyses and additional information to specifically address issues previously noted by the FDA in its December 27, 2013 Complete Response Letter. The company resubmitted the sBLA earlier this month following constructive discussions with the agency.



……..
To comment - click the comment link shown below
Share our Articles with others
……
MS Views and News / Stu's Views & MS News 
provide education, information and resources 
for those affected by Multiple Sclerosis

To Keep CURRENT  and up to date with MS News and Information
Sign-up at:  www.msviewsandnews.org 

WATCH OUR MS EDUCATIONAL VIDEOS by Topic, found here: www.youtube.com/msviewsandnews

JOIN our Facebook Page: www.facebook.com/msviewsandnews


 -------------

Thank you   

Stu's Views & MS News, is a publication of: 
…………………….


No comments: